Listed Biotechnology Companies P
This Page Last Updated On 2/12/2025
Recently established Australian company drawing together US and German technology to develop treatments for cancer and other diseases. Collaborations in place with Takeda, Astra Zeneca and Debiopharm. Company listed in July 2007 and prices rose 50% immediately but were barely 2% of the prospectus price a year later. Market cap of $23 million (down 79% in 2008 but up 25% in 2009 with a jump due to speculation over prospective clinical trials). Prices down 22% with a market cap of $23 million at the end of 2010 following R&D agreement with CSL, achievement of first milestone, a new funding facility, new funding and FDA approval for orphan drug indication. There was an increase and decline in 2011 (down 68% at $10 million) with further announcements of advancements, appointment of new Managing Director and new funds raised. New fund-raising in 2012 increased company value to $18 million (shares down 8%). There was a 24% decrease in 2013 to $15 million with clinical trials promising and a recovery with product getting Orphan Drug Designation by FDA and new joint clinical trial (eventually up 37% at $34 million with new funds raised). There was a 69% decline in 2014 with company value at $11 million with limited positive clinical results and resignation of CEO. There has been a further 44% decline in 2015 to $6 million with continuing delay in clinical trial due to manufacturing issues, appointment of new CEO and new licensing deal with China. Restructuring of company was continuing with retirement of COO and closing of facility in Germany. Down 25% in 2016 at $4 million with acquisition of new technology from Yale for application to cancer treatment. Shares were down 17% in 2017 with company value of $4 million, but promising preclinical results led to in a speculative jump in prices (eventually up 283% at $18 million). There was a further 17% increase in 2018 to $29 million with release of positive preclinical data on efficacy and raising of further funds. There was a 26% decrease in 2019 to $21 million with an insurance payment boosting the company's coffers, promotion of new technology platform and promising preclinical results. There was a 20% increase in 2020 to $43 million with new funds being raised. There was a 54% increase in 2021 to $76 million with publication indicating PAB-DX1 could have use as a brain cancer therapy and potential delays to projected clinical trials as well as new fund raising. There was a 27% decrease in 2022 to $56 million, with no explanation for a recent increase. There was a 70% decrease in 2023 to $16 million with key trial to commence in 2024. There was a 50% decrease in 2024 to $8 million with concerns expressed about the stability of the lead compound prior to trials. There has been a 42% decrease in 2025 to $11.9 million with Board changes and CEO position made redundant. Company undertook a 15:1 consolidation in October and is acquiring a small pharma company.. (2/12/25)
Company repurposing pentosan polysulphate sodium for the treatment of bone marrow edema listed in late August 2015 In 2015 following listing, shares fell 6% to company value of $29 million but rose 18% in 2016 to $39 million with a move into clinical trials for treatment of allergic rhinitis and viral arthritis and fund raising oversubscribed. Shares up 73% to $69 million in 2017 with new application for treating Ross River virus infection indicated and clinical trial in hay fever almost completed. Clinical trial not meeting endpoints resulted in more than a 50% drop in share prices (then down 27% to $29 million), However a publication indicating the role of pentosan polysulphate sodium in treating osteoarthritis resulted in a 79% turnaround in September. Eventually down 28% at $34 million with positive trial results announced, new funds raised and new clinical trials on schedule. There was a 275% increase in 2018 to $147 million with continuing positive trial results fuelling speculation, successful new fund raising and new licensing agreement. There was a 179% increase to $577 million in 2019 with a substantial fund raising completed and clinical data continuing to look positive with first IND to the FDA accepted. There was a 13% decrease in 2020 to $584 million with the strengthening of management. There was a 26% decrease in 2021 to $429 million with FDA review of NDA submission taking longer than expected and revenues starting from use in the Special Access Scheme. There was a 33% temporary increase in November with FDA approval of the IND. There was a 25% decrease in 2022 to $393 million with FDA Fast Track Designation gained, key trial commencing in US, appointment of US-based CEO who is now leaving, new fund raising completed and positive trial results. There was a 70% decrease in 2023 to $149 million following fund raising for Phase III trial. There was a 12% decrease in 2024 to $146 million with clinical trials promising and recent speculation about FDA approval resulting in a doubling of share price. There has been a 9% decrease in 2025 to $146 million with funds raised for osteoarthritis clinical trial . (26/11/25)
New Zealand based company formed in 2001 to commercialise a bladder cancer diagnostic Cxbladder, which is in the market. Company listed in September 2021. There was a 64% decrease in 2022 to $365 million with sales increasing and diagnostic improving but there are questions about reimbursement on Cxbladder in the US resulting in 33% drop. There was a 78% decrease in 2023 to $80 million with quarterly tests up 36% on the period a year before but announcement that Medicare would cease coverage of CxBladder tests in the US market resulted in an 82% drop in share prices in June to $ 67 million with some recovery following announcement that some companies would reimburse costs. There was a 38% increase in 2024 to $110 million with diagnostic test gaining higher profile in the industry and revenues up as well as outlook in the US market improving. There has been a 4% decrease in price in 2025 to $133 million with ending of reimbursement for Cxbladder. in the US. An announcement that the American Urological Association supported CxBladder test resulted in 110% share increase but this area remains uncertain as revenues appear to be declining. (28/11/25)
Antisense Therapeutics changed its name to Percheron Therapeutics in early 2024. Following its listing 1in 2001, shares drifted down 75% as it was known from the outset that commercialisation of the company's products would take some time. The shares were given a fillip in August 2003 as part of an overall boost in biotech stocks and, surprisingly, prices remained high for a while before gradually declining. However, the announcement in March 2005 of complications with a competitor's product directed at the same target led to a sharp 60% drop and some temporary recovery associated with reinitiation of clinical trials, although a proof of concept study which indicated limited effect reversed this (down 71% in 2005). In 2006, recommencement of a clinical trial and a proposal for refinancing of the company resulted in an improvement (100% in five months to end January 2007) and prices were the same as at the beginning of 2006. There was a modest 5% price rise in 2007. In 2008 there was a 100% increase due to the deal with Teva Pharmaceuticals and positive trial results (eventually down 17% in 2008). The market cap of the company was $29 million in early 2010 (up 57% in 2009 and down 11% in 2010) which we considered was high in view of cash reserves of $3 million and was driven by future expectations as Teva had made milestone payments. When Teva advised in March 2010 that it was discontinuing development and termination of the licence, there was a steep fall in value with some recovery to $8 million (down 87% in 2010) on expectation of new licensing opportunities and new funds raised and up 229% in 2011 at $23 million with excessive speculation over early stage clinical trials. There was a decline to $16 million in 2012 (down 52%) with new funds raised but no explanation for a temporary rise which ended when agreement with Afandin lapsed. There was a 36% increase to $22 million in 2013 following developments on clinical trials and share consolidation having little impact on company value. There was a 40% decline in 2014 with company value at $14 million with new fund raising completed and company searching for partnership deals to assist future development. There was a short term 60% increase in 2015 to $28 million with signing of licensing agreements in Sweden and the Netherlands and licensing revenues providing some profitability This dissipated to a degree (eventually down 21% at $13 million). There was a further 49% decline to $6 million in 2016 with announcement that licensing partner Strongbridge Biopharma was terminating its licence to ATL1103 and new application being sought for ATL1102 in multiple sclerosis. There was a 33% decrease in 2017 to $4 million with positive clinical trial results and slow progress to next trials. There was a 29% decrease in 2018 to $6 million following new fund raising and commencement of new clinical trial. There was a 200% share price jump to $22 million in October (eventually up 8% to $10 million). There was a further 88% increase to $21 million in 2019 due to speculation over a trial in process and raising of new funds. Preliminary results for the clinical trial were positive leading to a further 64% jump in prices (eventually up 246% in 2019 to $42 million.) There was a 44% increase in 2020 to $75 million with new funds raised, positive clinical trial results and orphan drug designation gained. There was a further 50% increase in 2021 to $130 million with more positive data on applications of products and new funds raised. There was a 50% decrease in 2022 to $65 million. There was a 43% decrease in 2023 to $50 million with replacement of retiring Managing Director in place and funds raised. The company changed its name to Percheron Therapeutics (ASX:PER) in early 2024. There was then little change in 2024 at $64 million but announcement in December that key clinical trial did not meet endpoints resulted in an 88% share drop to $7.6 million. There has been a 14% increase in 2025 to $8.7 million with plans being made for the company to move forward with new technology on cancer treatment and move by shareholders to remove the Chairman and one or more directors in early March was unsuccessful. (25/11/25)
Company with the vague aim of development of diagnostic tests for common diseases and therapeutic drugs listed in April 2015 and prices increased 200% on listing but subsequently settled back (eventually up 27% at value of $14 million). There was a 12% decrease in 2016 with company value at $15 million following an analyst report and raising of funds and an 8% increase in 2017 to $15 million with partnership with Dimerix (AX:DXB) on diagnosis and treatment of chronic kidney disease. There was a 43% increase in 2018 to $31 million with strategic alliance with (10% investment in but now sold ) Adelaide diagnostic company, raising of further funds through options and agreements to launch diagnostic in US, Mexican and European markets and production of commercial kits as well as new agreement on kidney disease developments with Janssen Research and Development. There was an 18% decrease in 2019 with a temporary recover4y to $21 million (down 31%) due to hiccups in developing US market for new product and good promotion in target US markets. However announcement of launch of kidney disease diagnostic in Spain resulted in a 30% increase to $31 million (down 29% at $25 million in 2019 with new funds raised). There was a 194% increase in 2020 to $83 million with CE registration gained for its key diagnostic and validation of the diagnostic in an international study with new distribution in Italy. There was a 53% speculative increase in 2021 to $128 million with indications of economic benefits of the Promarker D test, moves to seek reimbursement and new analytical contract signed. There was a 22% decrease in 2022 to $110 million with progress being made on endometriosis test and spin off of company diagnosing oxidative stress. There was a 6% decrease in 2023 to $109 million with reimbursement for PromarkerD test in US approved and agreement with Sonic Healthcare extended but lack of approval in Australia causing problems. US Medicare indication of reimbursement payments resulted in a 23% increase in share prices. Company also presented endometriosis diagnostic test at international conference. There was an 11% decrease in 2024 to $105 million with termination of exclusive distribution agreement with Sonic Healthcare US due to milestones not being met which resulted in 40% price drop and more evidence of usefulness of Promarker diagnostic test in detecting endometriosis and muscle damage in elite runners . There has been a further 43% decrease in 2025 to $75 million with launch of Promarker D test in Australia and the US and funding raised to support commercialisation of suite of diagnostic tests for kidney disease, oesophageal cancer and endometriosis. (2/12/25)
Originally Metabolic Pharmaceuticals which listed in 1999 and by 2007, market cap had reached $245 million which in our view was very high as a result of speculation and we expected subsequent falls. in the share price. It was therefore not surprising that the stock fell 82% in February 2007 when trials of its lead compound for treating obesity were not successful. There was a further 50% fall with announcement that clinical trials on a pain drug were discontinued. Company halted work on oral peptide delivery, closed laboratories and was looking to outlicense its osteoporosis drug. This culminated in July 2008 with1 announce14nt to acquire PolyNovo Biomaterials which was rejected by shareholders in November but in December 2008, the company took a 66% position in PolyNovo and eventually 100%. Shares rose 15% in 2009 with market cap of $9 million. In November 2009, company changed name to Calzada and acquired Xceed Capital's and CSIRO's remaining shareholding in PolyNovo under a share swap. In 2010, shares fell then recovered and were down 13% at $9 million with the Xceed holding in Calzada sold and the Calzada 17% holding in Avexa sold. Calzada proposed to vend in Metabolic Pharmaceuticals and its IP into ATOS Wellness (ASX:ATW) for 50% of company but this was not successful. Through its shareholding, Calzada was seeking to exert influence over Avexa and this turned into an unpleasant and unedifying exchange between the Boards of the two companies. Eventually Calzada sold its holding in Avexa and concentrated on its deal with Phosphagenics for a cosmeceutical based on AOD9604 with some recovery in the share price. There was a 115% increase in 2011 to $19 million based on speculation on possible application of AOD9604 to treatment of osteoporosis and positive results from Polynovo leading to a clinical trial. There was a 16% decrease in 2012 to $16 million with no significant improvement in financials. There was a 68% recovery in 2013 to $33 million with announcement of positive clinical trials and new arrangements and a further 14% increase in 2014 to $38 million on speculation over FDA clearance and board and structural changes which resulted in a name change to Polynovo at the end of November 2014 and divestment of the Metabolic Pharmaceuticals business. There has been a 222% increase in 2015 to $159 million with new CEO promoting the business, clinical support staff engaged, a new clinical trial to obtain CE mark for BTM (Biodegradable Temporising Matrix), FDA approval, a new contract with US Department of Health and more funds raised. There was no change in 2016 with company value at $163 million with acquisition of new technology and a decision to use its own sale force to sell its product in the US market. There was a 79% increase in 2017 to $340 million with PNV's matrix product being successfully used in the US and a possible new application for NovoSorb, losses for the year up and new funds raised. There was a 14% increase in 2018 with company value at $393 million with revenues and losses increasing and signing of a new program for a breast device. There has been a 231% increase in 2019 to $1.302 billion with positive promotion overseas, appointment of VP to promote the US market, a COO to drive in house operations. NovoSorb BTM gaining CE Mark and revenue break even with sales of $1 million per month. There was a 97% increase in 2020 to $2.565 billion with revenues up 60% and BARDA providing support for key clinical trial approved by FDA. However there was a 61% fall to $1.008 billion in 2021 due to operations being affected by Covid pandemic reducing sales of product but revenue outlook for the year is improving considerably and key trials are progressing. Managing Director is retiring and company in search for new leader. There was a 32% increase in 2022 to $1.390 billion with good financials announced recently, increasing new year sales, director share-buying increasing prices, a new CEO and move to enter large Indian market. There was a share price drop late in 2022 associated with large fund raising. There was an 18% decrease in 2023 to $1.135 billion despite sales projections improving significantly. There was a 23% increase in 2024 to $1.409 billion with financials improving and break even achieved. There has been a 40% decrease in 2025 to $850 million with outlook improving but sales growth lower than expected and clinical studies positive. There was a sudden unexpected departure of the CEO. (29/11/25)
Company previously called Virax Holdings Limited and name changed to Prescient Therapeutics after two cancer companies were acquired in 2014, Pathway Oncology and AKTivate Therapeutics, and a subsequent share consolidation. Shares down 58% in 2014 to company value of $5 million and down 13% in 2015 to $9 million with funds raised. There was a recovery in 2016 with FDA approval for trial an17 substantial funding raised (eventually down 10% at $18 million). There was an 8% increase in 2017 with company value at $20 million but the announcement in May of a severe adverse event during a clinical trial resulted in a 40% drop in prices. There has been some recovery following announcement of new indication for lead product PTX-100 (eventually down 22% at $14 million). There was a 3% increase in 2018 to $15 million with speculation about clinical trial results and new collaborations in the US and there was a 12% decrease in 2019 to $24 million with major fund raising completed and clinical trials producing promising results. There was a 10% decrease in 2020 to $34 million with a recent 25% increase associated with licensing arrangement for a cancer treatment platform with universities in Pennsylvania and Oxford. There was an unexplained 243% increase in 2021 to $150 million. There was a 41% decrease in 2022 to $97 million with new cancer therapy unveiled and funds raised. There was a 54% decrease in 2023 to $50 million. There was a 19% decrease in 2024 to $40 million. There has been a 62% increase in 2025 to $85 million with technical difficulties overcome, funds raised and Fast Track Designation for PTX-100. (27/11/25)
Drug discovery company which listed at the end of March 2005 at a premium of 30%, and retained this value through 2005. The company was promoted at a time of downturn in the sector and it was reasonable to expect that prices would decline once initial euphoria had dissipated. In 2006, the shares of the company rose, fell then recovered and rose 88% overall associated with heightened expectations for company developments and new indications. This continued initially into 2007 but with some subsequent fall in prices due to lack of noticeable progress. This resulted in decision to change CEOs at the end of the year. We consider that longer term share trends will be similar to current levels: market cap of $18 million at end of 2010 was fair (down 60% in 2007 and down 81% in 2008 but up 238% in 2009 associated with engagement of investment advisors and speculation over collaborations with large pharmas including Roche and Pfizer). There was a 53% decline in 2010 despite an agreement with Medimmune and Pfizer. There were price oscillations in 2011 to $18 million (eventually down 38%) due to speculation resulting from promotion by analysts, further fund raising and new and extended collaboration agreements. Improving financials in 2012 appeared to have had limited effect on prices with falls unexplained (down 38% to $11 million) with licensing of technology into the cosmetics industry and new fund raising. There was an extension of existing collaborative agreements and a new commercialisation agreement in 2013, none of which appeared to have had an effect on the bottom line or the share price although there was a 32% drop to $10 million with recapitalisation in train. Underwritten entitlement issue 87% acceptance and 59% share rise in 2014 to company value of $16 million with emphasis on international collaborations. However this was reversed when Janssen decided not to continue with collaboration and now a new agreement has been signed with Genentech (up 12% in 2014 at $19 million with more funds raised and new agreement with Genentech). There was a 26% increase in 2015 to $24 million without a satisfactory explanation by the company and then a doubling of price with announcement of positive research results with Phylogica's fusion products. This was followed by a fall with announcement of entitlement issue to raise further funds (in 2015 down 32% at $26 million) following fund raising. Shares up 92% in 2016 to company value of $50 million. There was a further 60% increase in 2017 to $85 million with funds raised and appointment of new CEO and CSO as well as new company strategy moving from product development to platform commercialisation. There was a 30% decrease in 2018 to $68 million with substantial changeover of Board and management and raising of funds and a 121% increase in 2019 to $182 million with preclinical trials promising and a move to rebrand the company as PYC Therapeutics. There was a 137% increase in 2020 to $466 million with appointment of US-based Managing Director, opening of office in Boston MA, speculation over forthcoming clinical trial, announced treatment for retinitis pigmentosa and raising of substantial new funds. There was an 8% decrease in 2021 to $429 million with trials progressing. There was a 49% decrease in 2022 to $219 million with a recent rise resulting from market promotion and toxicology tests successful. There was a 59% increase in 2023 to $411 million with market promotion and second potential product added to portfolio as well as commencement of key clinical trial. Company has raised substantial funds for coming clinical trials. There was a 20% increase in 2024 at $616 million with substantial funds raised and FDA granting orphan drug and rare pediatric drug designations to lead candidate with promising clinical results . There was a 10:1 share consolidation in November. There has been a 13% increase in 2025 to $866 million with regulatory approval for new trial, extension of current trial and substantial funds raised. However resignation of MD and replacement with Chairman resulted in 30% share price fall. This has been partly reversed with reappointment of the MD and reorganisation of the Board with a new independent Chairman. (27/11/25)
